Clinical Trial Update: Optimal Timing of BR55 CEUS of the Ovaries [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the optimal timing of BR55 ultrasound contrast agent (CEUS) for imaging the ovaries in ovarian cancer; the trial was terminated and res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• BR55 CEUS (BR55 ultrasound contrast agent)

Snippet

Sponsor: Bracco Diagnostics, Inc | Conditions: Ovarian Cancer | Phase 2 | Status: TERMINATED | Results posted: 2024-08-23